Table of Contents Author Guidelines Submit a Manuscript
Mediators of Inflammation
Volume 2017, Article ID 7462945, 12 pages
https://doi.org/10.1155/2017/7462945
Research Article

TSG-6 Downregulates IFN-Alpha and TNF-Alpha Expression by Suppressing IRF7 Phosphorylation in Human Plasmacytoid Dendritic Cells

Department of Paediatrics and Adolescent Medicine, LKS Faculty of Medicine, The University of Hong Kong, Pokfulam, Hong Kong

Correspondence should be addressed to P. P. W. Lee; kh.ukh@eelwpp

Received 7 November 2016; Revised 17 January 2017; Accepted 14 February 2017; Published 6 March 2017

Academic Editor: Soh Yamazaki

Copyright © 2017 L. Kui et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. K. B. Elkon and V. V. Stone, “Type I interferon and systemic lupus erythematosus,” Journal of Interferon and Cytokine Research, vol. 31, no. 11, pp. 803–812, 2011. View at Publisher · View at Google Scholar · View at Scopus
  2. R. M. Steinman and H. Hemmi, “Dendritic cells: translating innate to adaptive immunity,” Current Topics in Microbiology and Immunology, vol. 311, pp. 17–58, 2006. View at Google Scholar · View at Scopus
  3. L. Chaperot, A. Blum, O. Manches et al., “Virus or TLR agonists induce TRAIL-mediated cytotoxic activity of plasmacytoid dendritic cells,” The Journal of Immunology, vol. 176, no. 1, pp. 248–255, 2006. View at Publisher · View at Google Scholar · View at Scopus
  4. N. Kadowaki, S. Ho, S. Antonenko et al., “Subsets of human dendritic cell precursors express different toll-like receptors and respond to different microbial antigens,” Journal of Experimental Medicine, vol. 194, no. 6, pp. 863–869, 2001. View at Publisher · View at Google Scholar · View at Scopus
  5. J. Dai, N. J. Megjugorac, S. B. Amrute, and P. Fitzgerald-Bocarsly, “Regulation of IFN regulatory factor-7 and IFN-α production by enveloped virus and lipopolysaccharide in human plasmacytoid dendritic cells,” The Journal of Immunology, vol. 173, no. 3, pp. 1535–1548, 2004. View at Publisher · View at Google Scholar · View at Scopus
  6. B. Barnes, B. Lubyova, and P. M. Pitha, “On the role of IRF in host defense,” Journal of Interferon and Cytokine Research, vol. 22, no. 1, pp. 59–71, 2002. View at Publisher · View at Google Scholar · View at Scopus
  7. L. Rönnblom, “Potential role of IFNα in adult lupus,” Arthritis Research & Therapy, vol. 12, supplement 1, article no. S3, 2010. View at Publisher · View at Google Scholar
  8. T. Kawai, S. Sato, K. J. Ishii et al., “Interferon-α induction through Toll-like receptors involves a direct interaction of IRF7 with MyD88 and TRAF6,” Nature Immunology, vol. 5, no. 10, pp. 1061–1068, 2004. View at Publisher · View at Google Scholar · View at Scopus
  9. S. J. Gibson, J. M. Lindh, T. R. Riter et al., “Plasmacytoid dendritic cells produce cytokines and mature in response to the TLR7 agonists, imiquimod and resiquimod,” Cellular Immunology, vol. 218, no. 1-2, pp. 74–86, 2002. View at Publisher · View at Google Scholar · View at Scopus
  10. K. Hoshino, T. Sugiyama, M. Matsumoto et al., “IκB kinase-α is critical for interferon-α production induced by Toll-like receptors 7 and 9,” Nature, vol. 440, no. 7086, pp. 949–953, 2006. View at Publisher · View at Google Scholar · View at Scopus
  11. T. Bárdos, R. V. Kamath, K. Mikecz, and T. T. Glant, “Anti-inflammatory and chondroprotective effect of TSG-6 (tumor necrosis factor-α-stimulated gene-6) in murine models of experimental arthritis,” American Journal of Pathology, vol. 159, no. 5, pp. 1711–1721, 2001. View at Publisher · View at Google Scholar · View at Scopus
  12. L. Liu, H. Song, H. Duan et al., “TSG-6 secreted by human umbilical cord-MSCs attenuates severe burn-induced excessive inflammation via inhibiting activations of P38 and JNK signaling,” Scientific Reports, vol. 6, Article ID 30121, 2016. View at Publisher · View at Google Scholar · View at Scopus
  13. V. Maina, A. Cotena, A. Doni et al., “Coregulation in human leukocytes of the long pentraxin PTX3 and TSG-6,” Journal of Leukocyte Biology, vol. 86, no. 1, pp. 123–132, 2009. View at Publisher · View at Google Scholar · View at Scopus
  14. L. Ye, R. Mora, N. Akhayani, C. C. Haudenschild, and G. Liau, “Growth factor and cytokine-regulated hyaluronan-binding protein TSG-6 is localized to the injury-induced rat neointima and confers enhanced growth in vascular smooth muscle cells,” Circulation Research, vol. 81, no. 3, pp. 289–296, 1997. View at Publisher · View at Google Scholar · View at Scopus
  15. C. Mindrescu, G. J. Thorbecke, M. J. Klein, J. Vilek, and H.-G. Wisniewski, “Amelioration of collagen-induced arthritis in DBA/1J mice by recombinant TSG-6, a tumor necrosis factor/interleukin-1-inducible protein,” Arthritis and Rheumatism, vol. 43, no. 12, pp. 2668–2677, 2000. View at Publisher · View at Google Scholar · View at Scopus
  16. D.-K. Kim, H. Choi, H. Nishida et al., “Scalable production of a multifunctional protein (TSG-6) that aggregates with itself and the CHO cells that synthesize It,” PLoS ONE, vol. 11, no. 1, Article ID e0147553, 2016. View at Publisher · View at Google Scholar · View at Scopus
  17. A. M. Foskett, N. Bazhanov, X. Ti, A. Tiblow, T. J. Bartosh, and D. J. Prockop, “Phase-directed therapy: TSG-6 targeted to early inflammation improves bleomycin-injured lungs,” American Journal of Physiology—Lung Cellular and Molecular Physiology, vol. 306, no. 2, pp. L120–L131, 2014. View at Publisher · View at Google Scholar · View at Scopus
  18. C. Mindrescu, A. A. M. Dias, R. J. Olszewski, M. J. Klein, L. F. L. Reis, and H.-G. Wisniewski, “Reduced susceptibility to collagen-induced arthritis in DBA/1J mice expressing the TSG-6 transgene,” Arthritis and Rheumatism, vol. 46, no. 9, pp. 2453–2464, 2002. View at Publisher · View at Google Scholar · View at Scopus
  19. J. Y. Oh, G. W. Roddy, H. Choi et al., “Anti-inflammatory protein TSG-6 reduces inflammatory damage to the cornea following chemical and mechanical injury,” Proceedings of the National Academy of Sciences of the United States of America, vol. 107, no. 39, pp. 16875–16880, 2010. View at Publisher · View at Google Scholar · View at Scopus
  20. D. J. Prockop and J. Y. Oh, “Mesenchymal stem/stromal cells (MSCs): role as guardians of inflammation,” Molecular Therapy, vol. 20, no. 1, pp. 14–20, 2012. View at Publisher · View at Google Scholar · View at Scopus
  21. Y. Qi, D. Jiang, A. Sindrilaru et al., “TSG-6 released from intradermally injected mesenchymal stem cells accelerates wound healing and reduces tissue fibrosis in murine full-thickness skin wounds,” Journal of Investigative Dermatology, vol. 134, no. 2, pp. 526–537, 2014. View at Publisher · View at Google Scholar · View at Scopus
  22. D. P. Dyer, C. L. Salanga, S. C. Johns et al., “The anti-inflammatory protein TSG-6 regulates chemokine function by inhibiting chemokine/glycosaminoglycan interactions,” The Journal of Biological Chemistry, vol. 291, no. 24, pp. 12627–12640, 2016. View at Publisher · View at Google Scholar · View at Scopus
  23. H. Choi, R. H. Lee, N. Bazhanov, J. Y. Oh, and D. J. Prockop, “Anti-inflammatory protein TSG-6 secreted by activated MSCs attenuates zymosan-induced mouse peritonitis by decreasing TLR2/NF-κB signaling in resident macrophages,” Blood, vol. 118, no. 2, pp. 330–338, 2011. View at Publisher · View at Google Scholar · View at Scopus
  24. H.-G. Wisniewski, J.-C. Hua, D. M. Poppers, D. Naime, J. Vilček, and B. N. Cronstein, “TNF/IL-1-inducible protein TSG-6 potentiates plasmin inhibition by inter-α-inhibitor and exerts a strong anti-inflammatory effect in vivo,” The Journal of Immunology, vol. 156, no. 4, pp. 1609–1615, 1996. View at Google Scholar · View at Scopus
  25. R. H. Lee, J. M. Yu, A. M. Foskett et al., “TSG-6 as a biomarker to predict efficacy of human mesenchymal stem/progenitor cells (hMSCs) in modulating sterile inflammation in vivo,” Proceedings of the National Academy of Sciences of the United States of America, vol. 111, no. 47, pp. 16766–16771, 2014. View at Publisher · View at Google Scholar · View at Scopus
  26. T. Kato, M. Okumi, M. Tanemura et al., “Adipose tissue-derived stem cells suppress acute cellular rejection by TSG-6 and CD44 interaction in rat kidney transplantation,” Transplantation, vol. 98, no. 3, pp. 277–284, 2014. View at Publisher · View at Google Scholar · View at Scopus
  27. J. Y. Oh, R. H. Lee, J. M. Yu et al., “Intravenous mesenchymal stem cells prevented rejection of allogeneic corneal transplants by aborting the early inflammatory response,” Molecular Therapy, vol. 20, no. 11, pp. 2143–2152, 2012. View at Publisher · View at Google Scholar · View at Scopus
  28. D. J. Kota, L. L. Wiggins, N. Yoon, and R. H. Lee, “TSG-6 produced by hMSCs delays the onset of autoimmune diabetes by suppressing Th1 development and enhancing tolerogenicity,” Diabetes, vol. 62, no. 6, pp. 2048–2058, 2013. View at Publisher · View at Google Scholar · View at Scopus
  29. S. Wang, J.-S. Lee, J. Hyun et al., “Tumor necrosis factor-inducible gene 6 promotes liver regeneration in mice with acute liver injury,” Stem Cell Research and Therapy, vol. 6, no. 1, article no. 20, 2015. View at Publisher · View at Google Scholar · View at Scopus
  30. D.-K. Kim, H. Nishida, S. Y. An, A. K. Shetty, T. J. Bartosh, and D. J. Prockop, “Chromatographically isolated CD63+CD81+ extracellular vesicles from mesenchymal stromal cells rescue cognitive impairments after TBI,” Proceedings of the National Academy of Sciences of the United States of America, vol. 113, no. 1, pp. 170–175, 2016. View at Publisher · View at Google Scholar · View at Scopus
  31. K. Sacre, L. A. Criswell, and J. M. McCune, “Hydroxychloroquine is associated with impaired interferon-alpha and tumor necrosis factor-alpha production by plasmacytoid dendritic cells in systemic lupus erythematosus,” Arthritis Research and Therapy, vol. 14, no. 3, article no. R155, 2012. View at Publisher · View at Google Scholar · View at Scopus
  32. R. Willis, A. M. Seif, G. McGwin Jr. et al., “Effect of hydroxychloroquine treatment on pro-inflammatory cytokines and disease activity in SLE patients: data from LUMINA (LXXV), a multiethnic US cohort,” Lupus, vol. 21, no. 8, pp. 830–835, 2012. View at Publisher · View at Google Scholar · View at Scopus
  33. J. Liang, D. Jiang, J. Griffith et al., “CD44 is a negative regulator of acute pulmonary inflammation and lipopolysaccharide-TLR signaling in mouse macrophages,” The Journal of Immunology, vol. 178, no. 4, pp. 2469–2475, 2007. View at Publisher · View at Google Scholar · View at Scopus
  34. P. M. Wolny, S. Banerji, C. Gounou et al., “Analysis of CD44-hyaluronan interactions in an artificial membrane system: insights into the distinct binding properties of high and low molecular weight hyaluronan,” Journal of Biological Chemistry, vol. 285, no. 39, pp. 30170–30180, 2010. View at Publisher · View at Google Scholar · View at Scopus
  35. H.-G. Wisniewski, R. Maier, M. Lotz et al., “TSG-6: a TNF-, IL-1-, and LPS-inducible secreted glycoprotein associated with arthritis,” The Journal of Immunology, vol. 151, no. 11, pp. 6593–6601, 1993. View at Google Scholar · View at Scopus
  36. H.-G. Wisniewski and J. Vilček, “TSG-6: an IL-1/TNF-inducible protein with anti-inflammatory activity,” Cytokine and Growth Factor Reviews, vol. 8, no. 2, pp. 143–156, 1997. View at Publisher · View at Google Scholar · View at Scopus
  37. The Canadian Hydroxychloroquine Study Group, “A randomized study of the effect of withdrawing hydroxychloroquine sulfate in systemic lupus erythematosus,” The New England Journal of Medicine, vol. 324, no. 3, pp. 150–154, 1991. View at Publisher · View at Google Scholar · View at Scopus
  38. G. S. Alarcón, G. McGwin, A. M. Bertoli et al., “Effect of hydroxychloroquine on the survival of patients with systemic lupus erythematosus: data from LUMINA, a multiethnic US cohort (LUMINA L),” Annals of the Rheumatic Diseases, vol. 66, no. 9, pp. 1168–1172, 2007. View at Publisher · View at Google Scholar · View at Scopus
  39. N. Kasitanon, D. M. Fine, M. Haas, L. S. Magder, and M. Petri, “Hydroxychloroquine use predicts complete renal remission within 12 months among patients treated with mycophenolate mofetil therapy for membranous lupus nephritis,” Lupus, vol. 15, no. 6, pp. 366–370, 2006. View at Publisher · View at Google Scholar · View at Scopus
  40. D. Fernandez, E. Bonilla, N. Mirza, B. Niland, and A. Perl, “Rapamycin reduces disease activity and normalizes T cell activation-induced calcium fluxing in patients with systemic lupus erythematosus,” Arthritis and Rheumatism, vol. 54, no. 9, pp. 2983–2988, 2006. View at Publisher · View at Google Scholar · View at Scopus
  41. P. P. C. Boor, H. J. Metselaar, S. Mancham, L. J. W. Van Der Laan, and J. Kwekkeboom, “Rapamycin has suppressive and stimulatory effects on human plasmacytoid dendritic cell functions,” Clinical and Experimental Immunology, vol. 174, no. 3, pp. 389–401, 2013. View at Publisher · View at Google Scholar · View at Scopus
  42. W. Cao, S. Manicassamy, H. Tang et al., “Toll-like receptor-mediated induction of type I interferon in plasmacytoid dendritic cells requires the rapamycin-sensitive PI(3)K-mTOR-p70S6K pathway,” Nature Immunology, vol. 9, no. 10, pp. 1157–1164, 2008. View at Publisher · View at Google Scholar · View at Scopus
  43. N. Hay and N. Sonenberg, “Upstream and downstream of mTOR,” Genes and Development, vol. 18, no. 16, pp. 1926–1945, 2004. View at Publisher · View at Google Scholar · View at Scopus
  44. F. Lekmine, S. Uddin, A. Sassano et al., “Activation of the p70 S6 kinase and phosphorylation of the 4E-BP1 repressor of mRNA translation by type I interferons,” The Journal of Biological Chemistry, vol. 278, no. 30, pp. 27772–27780, 2003. View at Publisher · View at Google Scholar · View at Scopus
  45. S. Ning, J. S. Pagano, and G. N. Barber, “IRF7: activation, regulation, modification and function,” Genes and Immunity, vol. 12, no. 6, pp. 399–414, 2011. View at Publisher · View at Google Scholar · View at Scopus
  46. Q. Liang, H. Deng, C.-W. Sun, T. M. Townes, and F. Zhu, “Negative regulation of IRF7 activation by activating transcription factor 4 suggests a cross-regulation between the IFN responses and the cellular integrated stress responses,” The Journal of Immunology, vol. 186, no. 2, pp. 1001–1010, 2011. View at Publisher · View at Google Scholar · View at Scopus
  47. W. Lawrance, S. Banerji, A. J. Day, S. Bhattacharjee, and D. G. Jackson, “Binding of hyaluronan to the native lymphatic vessel endothelial receptor LYVE-1 is critically dependent on receptor clustering and hyaluronan organization,” The Journal of Biological Chemistry, vol. 291, no. 15, pp. 8014–8030, 2016. View at Publisher · View at Google Scholar · View at Scopus
  48. J. Lesley, I. Gál, D. J. Mahoney et al., “TSG-6 modulates the interaction between hyaluronan and cell surface CD44,” The Journal of Biological Chemistry, vol. 279, no. 24, pp. 25745–25754, 2004. View at Publisher · View at Google Scholar · View at Scopus
  49. M. E. Mummert, D. Mummert, D. Edelbaum, F. Hui, H. Matsue, and A. Takashima, “Synthesis and surface expression of hyaluronan by dendritic cells and its potential role in antigen presentation,” The Journal of Immunology, vol. 169, no. 8, pp. 4322–4331, 2002. View at Publisher · View at Google Scholar · View at Scopus
  50. H. Kawana, H. Karaki, M. Higashi et al., “CD44 suppresses TLR-mediated inflammation,” The Journal of Immunology, vol. 180, no. 6, pp. 4235–4245, 2008. View at Publisher · View at Google Scholar · View at Scopus